Results 151 to 160 of about 2,706,945 (355)
A technique for measuring the biological availability of copper of sheep, sing hypocupraemic ewes [PDF]
N. F. Suttle
openalex +1 more source
A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancer
Lung cancer cells were spiked into donor blood to evaluate the recovery rates of the following circulating tumor cell (CTC) enrichment technologies: CellMag™, EasySep™, RosetteSep™, Parsortix® PR1, and Parsortix® Prototype systems. Each method's advantages and disadvantages are described.
Volga M Saini+11 more
wiley +1 more source
Biological Availability of Fat-Soluble Vitamins: Vitamin A and Carotene [PDF]
D. E. Ullrey
openalex +1 more source
Cell‐free and extracellular vesicle microRNAs with clinical utility for solid tumors
Cell‐free microRNAs (cfmiRs) are small‐RNA circulating molecules detectable in almost all body biofluids. Innovative technologies have improved the application of cfmiRs to oncology, with a focus on clinical needs for different solid tumors, but with emphasis on diagnosis, prognosis, cancer recurrence, as well as treatment monitoring.
Yoshinori Hayashi+6 more
wiley +1 more source
Sparsity is All You Need: Rethinking Biological Pathway-Informed Approaches in Deep Learning [PDF]
Biologically-informed neural networks typically leverage pathway annotations to enhance performance in biomedical applications. We hypothesized that the benefits of pathway integration does not arise from its biological relevance, but rather from the sparsity it introduces.
arxiv
Biological Availability to Chicks of Manganese from Different Inorganic Sources [PDF]
L. T. Watson+3 more
openalex +1 more source
This study demonstrates that KRAS and GNAS mutations are more prevalent in patients with resected intraductal papillary mucinous neoplasms (IPMN) compared to those under clinical surveillance. GNAS mutations significantly differ between the two patient cohorts, indicating that their absence may serve as a potential biomarker to support conservative ...
Christine Nitschke+12 more
wiley +1 more source
Extravascular factor IX after gene therapy in hemophilia B, does it matter?
Gene therapy will very likely change the treatment paradigm of hemophilia B in the coming years. For the majority of patients, adjunctive exogenous factor (F)IX clotting factor concentrate will continue to be needed in case of surgery or bleeding ...
Quentin Van Thillo, Cédric Hermans
doaj
Biological Availability of Digoxin from Lanoxin Produced in the United Kingdom [PDF]
B. F. Johnson+4 more
openalex +1 more source
The LEXOVE prospective study evaluated plasma cell‐free extracellular vesicle (cfEV) dynamics using Bradford assay and dynamic light scattering in metastatic non‐small cell lung cancer patients undergoing first‐line treatments, correlating a ∆cfEV < 20% with improved median progression‐free survival in responders versus non‐responders.
Valerio Gristina+17 more
wiley +1 more source